Myelin Antigen Autoreactivity in Multiple Sclerosis

  • M. Vergelli
Part of the Topics in Neuroscience book series (TOPNEURO)


It is currently believed that disturbances in the regulation of autoantigen-specific T cells, with a breakdown of immunological tolerance to myelin components, is crucial for the pathogenesis of multiple sclerosis (MS). However, the target autoantigens of this immune reaction are yet unknown. In MS the immune reactivity to myelin proteins has been extensively investigated. To date, this work has primarily focused on the two major myelin proteins, proteolipid protein (PLP) and myelin basic protein (MBP), but there is increasing interest in reactivity to minor myelin components such as myelin oligodendrocyte glycoprotein (MOG). For these three myelin proteins, encephalitogenicity has been demonstrated upon injection with immune adjuvants in susceptible animal strains, and T cells specific for these antigens are sufficient to cause experimental autoimmune encephalomyelitis (EAE).


Multiple Sclerosis Experimental Autoimmune Encephalomyelitis Multiple Sclerosis Patient Myelin Basic Protein Experimental Allergic Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burns J, Rosenzweig A, Zweiman B, Lisak RP (1983) Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 81: 435–440PubMedCrossRefGoogle Scholar
  2. 2.
    Ota K, Matsui M, Milford EL et al. (1990) T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346: 183–187PubMedCrossRefGoogle Scholar
  3. 3.
    Martin R, Utz U, Coligan JE et al. (1992) Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87–106. J Immunol 148: 1359–1366PubMedGoogle Scholar
  4. 4.
    Pette M, Fujita K, Kitze B et al. (1990) Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40:1770–1776PubMedCrossRefGoogle Scholar
  5. 5.
    Chou YK, Vainiene M, Whitham R, et al. (1989) Response of human T lymphocyte lines to myelin basic protein: association of dominant epitopes with HLA-class II restriction molecules. J Neurol Sci 23: 207–216Google Scholar
  6. 6.
    Schlüsener H, Wekerle H (1985) Autoaggressive T lymphocyte lines recognize the encephalitogenic region of myelin basic protein; In vitro selection from unprimed rat T lymphocyte populations. J Immunol 135: 3128–3133Google Scholar
  7. 7.
    Genain CP, Lee-Parritz D, Nguyen M-H et al. (1994) In healthy primates, circulating autoreactive T cells mediate autoimmune disease. J Clin Invest 94: 1339–1345PubMedCrossRefGoogle Scholar
  8. 8.
    Olsson T, Wei Zhi W, Höjeberg B,et al. (1990) Autoreactive T Lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ. J Clin Invest 86: 981–985PubMedCrossRefGoogle Scholar
  9. 9.
    Bieganowska KD, Ausbel LJ, Modaber Y et al. (1997) Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J Exp Med 185: 1585–1594PubMedCrossRefGoogle Scholar
  10. 10.
    Olsson T, Sun J, Hillert J et al. (1992) Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur J Immunol 22: 1083–1087PubMedCrossRefGoogle Scholar
  11. 11.
    Joshi N, Usuku K, Hauser SL (1993) The T-cell response to myelin basic protein in familial multiple sclerosis: Diversity of fine specificity, restricting elements, and T-cell receptor usage. Ann Neurol 34: 385–393PubMedCrossRefGoogle Scholar
  12. 12.
    Martin R, Voskuhl R, Flerlage M et al. (1993) Myelin basic protein-specific T-cell responses in identical twins discordant or concordant for multiple sclerosis. Ann Neurol 34: 524–535PubMedCrossRefGoogle Scholar
  13. 13.
    Allegretta M, Nicklas JA, Sriram S, Albertini RJ (1990) T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247: 718–721PubMedCrossRefGoogle Scholar
  14. 14.
    Zhang J, Markovic-Plese S, Lacet B et al. (1994) Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 179: 973–984PubMedCrossRefGoogle Scholar
  15. 15.
    Lovett-Racke AE, Trotter JL, Lauber J et al. (1998) Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. J Clin Invest 101: 725–730PubMedCrossRefGoogle Scholar
  16. 16.
    Scholz C, Patton KT, Anderson DE et al. (1998) Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 160: 1532–1538PubMedGoogle Scholar
  17. 17.
    Richert JR, Reuben-Burnside CA, Deibler GE, Kies MW (1988) Peptide specificities of myelin basic protein-reactive human T-cell clones. Neurology 38: 739–742PubMedCrossRefGoogle Scholar
  18. 18.
    Pette M, Fujita K, Wilkinson D et al. (1990) Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc Natl Acad Sci USA 87: 7968–7972PubMedCrossRefGoogle Scholar
  19. 19.
    Martin R, Howell MD, Jaraquemada D et al. (1991) A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med 173: 19–24PubMedCrossRefGoogle Scholar
  20. 20.
    Meinl E, Weber F, Drexler K et al. (1993) Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 92: 2633–2643PubMedCrossRefGoogle Scholar
  21. 21.
    Vergelli M, Kaibus M, Rojo SC et al. (1997) T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. J Neuroimmunol 77: 195–203PubMedCrossRefGoogle Scholar
  22. 22.
    Muraro PA, Vergelli M, Kalbus M et al. (1997) Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111–129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell repertoire. J Clin Invest 100: 339–349PubMedCrossRefGoogle Scholar
  23. 23.
    Martin R, McFarland HF, McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10: 153–187PubMedCrossRefGoogle Scholar
  24. 24.
    Zamvil SS, Steinman L (1990) The T lymphocyte in experimental allergie encephalomyelitis. Annu Rev Immunol 8: 579–621PubMedCrossRefGoogle Scholar
  25. 25.
    Valli A, Sette A, Kappos L et al. (1993) Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 91: 616–628PubMedCrossRefGoogle Scholar
  26. 26.
    Vogt AB, Kropshofer H, Kaibacher H et al. (1994) Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol 153: 1665–1673PubMedGoogle Scholar
  27. 27.
    Wucherpfennig KW, Sette A, Southwood S et al. (1994) Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 179: 279–290PubMedCrossRefGoogle Scholar
  28. 28.
    Oksenber JR, Panzara MA, Begovich AB et al. (1993) Selection for T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362: 68–70CrossRefGoogle Scholar
  29. 29.
    Allegretta M, Albertini RJ, Howell MD et al. (1994) Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. J Clin Invest 94: 105–109PubMedCrossRefGoogle Scholar
  30. 30.
    Gold DP, Offner H, Sun D et al. (1991) Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3. J Exp Med 174: 1467–1476PubMedCrossRefGoogle Scholar
  31. 31.
    Steinman L, Waisman A, Altman D (1995) Major T-cell responses in multiple sclerosis. Mol Med Today 1: 79–83PubMedCrossRefGoogle Scholar
  32. 32.
    Hemmer B Vergelli M, Tranquill L et al. (1997) Human T-cell response to myelin basic protein peptide (83–99): extensive heterogeneity in antigen recognition, function and phenotype. Neurology 49: 1116–1126PubMedCrossRefGoogle Scholar
  33. 33.
    Wucherpfennig KW, Ota K, Endo N et al. (1990) Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science 248: 1016–1019PubMedCrossRefGoogle Scholar
  34. 34.
    Kotzin BL, Karuturi S, Chou YK et al. (1991) Preferential T-cell receptor Vβ-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc Natl Acad Sci USA 88: 9161–9165PubMedCrossRefGoogle Scholar
  35. 35.
    Vergelli M, Hemmer B, Utz U et al. (1996) Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99). Eur J Immunol 26: 2624–2634PubMedCrossRefGoogle Scholar
  36. 36.
    Wucherpfennig KW, Zhang J, Witek C et al. (1994) Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 152: 5581–5592PubMedGoogle Scholar
  37. 37.
    Hafler DA, Saadeh MG, Kuchroo V et al. (1996) TCR usage in human and experimental demyelinating diseases. Immunol Today 17: 152–159PubMedCrossRefGoogle Scholar
  38. 38.
    Ando DG, Clayton J, Kono D et al. (1989) Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 124: 132–143PubMedCrossRefGoogle Scholar
  39. 39.
    Baron JL, Madri JA, Ruddle NH et al. (1993) Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177: 57–68PubMedCrossRefGoogle Scholar
  40. 40.
    Kuchroo VK, Martin CA, Greer JM et al. (1993) Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol 151: 4371–4382PubMedGoogle Scholar
  41. 41.
    Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987) Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 37: 1097–1102PubMedCrossRefGoogle Scholar
  42. 42.
    Hartung HP, Hughes RAC, Taylor WA,et al. (1990) T cell activation in Guillain-Barré Syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 40: 215–218PubMedCrossRefGoogle Scholar
  43. 43.
    Sharief MK, Hentges R (1991) Association between tumor necrosis factor-α and disease progression in chronic progressive multiple sclerosis. N Engl J Med 325: 467–472PubMedCrossRefGoogle Scholar
  44. 44.
    Rieckmann P, Albrecht M, Kitze B et al. (1995) Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37: 82–88PubMedCrossRefGoogle Scholar
  45. 45.
    Martin R, McFarland HF (1995) Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 32: 121–182PubMedCrossRefGoogle Scholar
  46. 46.
    Tsuchida T, Parker KC, Turner RV, et al. (1994) Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci USA 91: 10859–10863PubMedCrossRefGoogle Scholar
  47. 47.
    Voskuhl RR, Martin R, Bergman C et al. (1993) T helper 1 (TH1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 15: 137–143PubMedCrossRefGoogle Scholar
  48. 48.
    Hemmer B, Vergelli M, Calabresi P et al. (1996) Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83–99). J Neurosci Res 45: 852–862PubMedCrossRefGoogle Scholar
  49. 49.
    Jaraquemada D, Martin R, Rosen-Bronson S et al. (1990) HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. J Immunol 145: 2880–2885PubMedGoogle Scholar
  50. 50.
    Martin R, Jaraquemada D, Flerlage M et al. (1990) Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 145: 540–548PubMedGoogle Scholar
  51. 51.
    Vergelli M, Le H, van Noort JM et al. (1996) A novel population of CD4+CD56+ myelin reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. J Immunol 157: 679–688PubMedGoogle Scholar
  52. 52.
    Vergelli M, Hemmer B, Muraro P et al. (1997) Human autoreactive CD4+ T cell clones use perforin — or Fas ligand-mediated pathways for target cell lysis. J Immunol 158: 2756–2761PubMedGoogle Scholar
  53. 53.
    Salvetti M, Ristori G, D’Amato M et al. (1993) Predominant and stable T cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis. Eur J Immuol 23: 1232–1239CrossRefGoogle Scholar
  54. 54.
    Uccelli A, Giunti D, Salvetti M et al. (1998) A restricted response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. Clin Exp Immunol 111: 186–192PubMedCrossRefGoogle Scholar
  55. 55.
    Correale J, Gilmore W, McMillan M et al. (1995) Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 154: 2959–2968PubMedGoogle Scholar
  56. 56.
    Hemmer B, Vergelli M, Pinilla C et al. (1998) Probing degeneracy in T-cell recognition using peptide combinatorial libraries — Importance for T-cell survival and autoimmunity. Immunol Today 19: 163–168PubMedCrossRefGoogle Scholar
  57. 57.
    Mason D (1998) A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 19: 395–404PubMedCrossRefGoogle Scholar
  58. 58.
    Vergelli M, Hemmer B, Kalbus M et al. (1997) Modifications of peptide ligands enhancing T cell responsiveness suggest a broad spectrum of stimulatory ligands for autoreactive T cells. J Immunol 158: 3746–3752PubMedGoogle Scholar
  59. 59.
    Hemmer B, Fleckenstein BT, Vergelli M et al. (1997) Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 185: 1651–1659PubMedCrossRefGoogle Scholar
  60. 60.
    Abo S, Bernard CCA, Webb M et al. (1993) Preparation of highly purified human myelin oligodendrocyte glycoprotein in quantities sufficient for encephalitogenicity and immunogenicity studies. Biochem Mol Biol Int 30: 945–958PubMedGoogle Scholar
  61. 61.
    Bernard CCA, Johns TG, Slavin A et al. (1997) Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 75: 77–88PubMedCrossRefGoogle Scholar
  62. 62.
    Genain CP, Nguyen MH, Letvin NL et al. (1995) Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 96: 2966–2974PubMedCrossRefGoogle Scholar
  63. 63.
    Genain CP, Abel K, Belmar N et al. (1996) Late complication of immune deviation therapy in a nonhuman primate. Science 274: 2054–2057PubMedCrossRefGoogle Scholar
  64. 64.
    Xiao BG, Linington C, Link H (1991) Antibodies to myelin oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol 31: 91–96PubMedCrossRefGoogle Scholar
  65. 65.
    Kerlero de Rosbo N, Milo R, Lees MB et al. (1993) Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 92: 2602–2608PubMedCrossRefGoogle Scholar
  66. 66.
    Sun J, Link H, Olsson T et al. (1991) T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 146: 1490–1495PubMedGoogle Scholar
  67. 67.
    Kerlero de Rosbo N, Hoffman M, Mendel I et al. (1997) Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol 27: 3059–3069PubMedCrossRefGoogle Scholar
  68. 68.
    Wallstrom E, Khademl M, Andersson M et al. (1998) Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA-DR2(15)+ multiple sclerosis. Eur J Immunol 28: 3329–3336PubMedCrossRefGoogle Scholar
  69. 69.
    Trotter JL, Hickey WF, van der Veen RC, Sulze L (1991) Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides. J Neuroimmunol 33: 55–62PubMedCrossRefGoogle Scholar
  70. 70.
    Sun JB, Olsson T, Wang WZ et al. (1991) Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 21: 1461–1468PubMedCrossRefGoogle Scholar
  71. 71.
    Pelfrey CM, Trotter JL, Tranquill LR, McFarland HF (1993) Identification of a novel T cell epitope of human proteolipid protein (residues 40–60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis. J Neuroimmunol 46: 33–42PubMedCrossRefGoogle Scholar
  72. 72.
    Pelfrey CM, Trotter JL, Tranquill LR, McFarland HF (1994) Identification of a second T cell epitope of human proteolipid protein (residues 89–106) recognized by proliferative and cytolytic CD4+ T cells from multiple patients. J Neuroimmunol 53:153–161PubMedCrossRefGoogle Scholar
  73. 73.
    Ohashi T, Yamamura T, Inobe J et al. (1995) Analysis of proteolipid protein (PLP)-specific T cells in multiple sclerosis: identification of PLP 95–116 as an HLA-DR2, w15-associated determinant. Int Immunol 7: 1771–1778PubMedCrossRefGoogle Scholar
  74. 74.
    Markovic-Plese S, Fukaura H, Zhang J et al. (1995) T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol 155: 982–992PubMedGoogle Scholar
  75. 75.
    Greer JM, Csurhes PA, Cameron KD et al. (1997) Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 120: 1447–1460PubMedCrossRefGoogle Scholar
  76. 76.
    Trotter JL, Pelfrey CM, Trotter AM et al. (1998) T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J Neuroimmunol 84:172–178PubMedCrossRefGoogle Scholar
  77. 77.
    Trotter JL, Damico CA, Cross AH et al. (1997) HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J Neuroimmunol 75: 95–103PubMedCrossRefGoogle Scholar
  78. 78.
    Zhang YD, Burger D, Saruhan M et al. (1993) The T-lymphocyte response against myelin-associated glycoprotein and myelin basic protein in patients. Neurology 43:403–407PubMedCrossRefGoogle Scholar
  79. 79.
    Link H, Sun JB, Wang Z et al. (1992) Virus-specific and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 38: 63–74PubMedCrossRefGoogle Scholar
  80. 80.
    Banki K, Colombo E, Sia F et al. (1994) Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J Exp Med 180: 1649–1663PubMedCrossRefGoogle Scholar
  81. 81.
    Rosener M, Muraro P, Riethmuller A et al. (1997) 2′,3′-cyclic nucleotide 3′-phosphodiesterase: a novel candidate autoantigen in demyelinating diseases. J Neuroimmunol 75: 28–34PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1999

Authors and Affiliations

  • M. Vergelli
    • 1
  1. 1.Department of Neurological and Psychiatric SciencesUniversity of FlorenceFlorenceItaly

Personalised recommendations